Imipenem/cilastatin/relebactam
Purpose The pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial activity, efficacy, safety, and current regulatory status of imipenem/cilastatin/relebactam are reviewed. Summary Imipenem/cilastatin/relebactam is a newly approved anti-infective combination of a well-established β-lactam a...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , |
| التنسيق: | article |
| منشور في: |
2021
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/13461 https://doi.org/10.1093/ajhp/zxab012 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://academic.oup.com/ajhp/article/78/8/674/6134520?login=true |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513490730876928 |
|---|---|
| author | Mansour, Hanine |
| author2 | Oweini, Ahmad E. L Chahine, Elias B. Karaoui, Lamis R. |
| author2_role | author author author |
| author_facet | Mansour, Hanine Oweini, Ahmad E. L Chahine, Elias B. Karaoui, Lamis R. |
| author_role | author |
| dc.creator.none.fl_str_mv | Mansour, Hanine Oweini, Ahmad E. L Chahine, Elias B. Karaoui, Lamis R. |
| dc.date.none.fl_str_mv | 2021 2022-04-06T12:41:57Z 2022-04-06T12:41:57Z 2022-04-06 |
| dc.identifier.none.fl_str_mv | 1079-2082 http://hdl.handle.net/10725/13461 https://doi.org/10.1093/ajhp/zxab012 Mansour, H., Ouweini, A. E., Chahine, E. B., & Karaoui, L. R. (2021). Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination. American Journal of Health-System Pharmacy, 78(8), 674-683. http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://academic.oup.com/ajhp/article/78/8/674/6134520?login=true |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | American Journal of Health-System Pharmacy |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Imipenem/cilastatin/relebactam A new carbapenem β-lactamase inhibitor combination |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | Purpose The pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial activity, efficacy, safety, and current regulatory status of imipenem/cilastatin/relebactam are reviewed. Summary Imipenem/cilastatin/relebactam is a newly approved anti-infective combination of a well-established β-lactam and a new β-lactamase inhibitor for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, and complicated intra-abdominal infections (cIAIs) caused by susceptible gram-negative bacteria in patients 18 years of age or older with limited or no alternative treatment options. The antibiotic is also indicated for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). The antibiotic is active in vitro against a wide range of pathogens, including multidrug-resistant (MDR) Pseudomonas aeruginosa and carbapenem-resistant Enterobacterales (CRE) such as Klebsiella pneumoniae carbapenemase. The addition of relebactam does not restore the activity of imipenem against metallo-β-lactamase (MBL)–producing Enterobacterales and carbapenem-resistant Acinetobacter baumannii. Two phase 3 clinical trials of imipenem/cilastatin/relebactam were conducted. In the RESTORE-IMI 1 trial, the efficacy and safety of imipenem/cilastatin/relebactam was found to be comparable to that of imipenem/cilastatin plus colistin for the treatment of infections caused by imipenem-nonsusceptible gram-negative bacteria in patients with HABP/VABP, cUTIs, and cIAIs, with a significantly lower incidence of nephrotoxicity reported with the new antibiotic. The RESTORE-IMI 2 trial demonstrated the noninferiority of imipenem/cilastatin/relebactam to piperacillin/tazobactam for the treatment of HABP/VABP. Commonly reported adverse events in clinical trials included anemia, elevated liver enzymes, electrolyte imbalances, nausea, vomiting, diarrhea, headache, fever, phlebitis and/or infusion-site reactions, and hypertension. Conclusion Imipenem/cilastatin/relebactam is a new β-lactam/β-lactamase inhibitor combination with activity against MDR gram-negative bacteria, including many CRE but excluding MBL-producing Enterobacterales and carbapenem-resistant Acinetobacter baumannii. It is approved for the treatment of cUTIs, cIAIs, and HABP/VABP. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_9a81ef1acce4cc6010a8608a74cea9e2 |
| identifier_str_mv | 1079-2082 Mansour, H., Ouweini, A. E., Chahine, E. B., & Karaoui, L. R. (2021). Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination. American Journal of Health-System Pharmacy, 78(8), 674-683. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/13461 |
| publishDate | 2021 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Imipenem/cilastatin/relebactamA new carbapenem β-lactamase inhibitor combinationMansour, HanineOweini, Ahmad E. LChahine, Elias B.Karaoui, Lamis R.Purpose The pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial activity, efficacy, safety, and current regulatory status of imipenem/cilastatin/relebactam are reviewed. Summary Imipenem/cilastatin/relebactam is a newly approved anti-infective combination of a well-established β-lactam and a new β-lactamase inhibitor for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, and complicated intra-abdominal infections (cIAIs) caused by susceptible gram-negative bacteria in patients 18 years of age or older with limited or no alternative treatment options. The antibiotic is also indicated for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). The antibiotic is active in vitro against a wide range of pathogens, including multidrug-resistant (MDR) Pseudomonas aeruginosa and carbapenem-resistant Enterobacterales (CRE) such as Klebsiella pneumoniae carbapenemase. The addition of relebactam does not restore the activity of imipenem against metallo-β-lactamase (MBL)–producing Enterobacterales and carbapenem-resistant Acinetobacter baumannii. Two phase 3 clinical trials of imipenem/cilastatin/relebactam were conducted. In the RESTORE-IMI 1 trial, the efficacy and safety of imipenem/cilastatin/relebactam was found to be comparable to that of imipenem/cilastatin plus colistin for the treatment of infections caused by imipenem-nonsusceptible gram-negative bacteria in patients with HABP/VABP, cUTIs, and cIAIs, with a significantly lower incidence of nephrotoxicity reported with the new antibiotic. The RESTORE-IMI 2 trial demonstrated the noninferiority of imipenem/cilastatin/relebactam to piperacillin/tazobactam for the treatment of HABP/VABP. Commonly reported adverse events in clinical trials included anemia, elevated liver enzymes, electrolyte imbalances, nausea, vomiting, diarrhea, headache, fever, phlebitis and/or infusion-site reactions, and hypertension. Conclusion Imipenem/cilastatin/relebactam is a new β-lactam/β-lactamase inhibitor combination with activity against MDR gram-negative bacteria, including many CRE but excluding MBL-producing Enterobacterales and carbapenem-resistant Acinetobacter baumannii. It is approved for the treatment of cUTIs, cIAIs, and HABP/VABP.Published2022-04-06T12:41:57Z2022-04-06T12:41:57Z20212022-04-06Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1079-2082http://hdl.handle.net/10725/13461https://doi.org/10.1093/ajhp/zxab012Mansour, H., Ouweini, A. E., Chahine, E. B., & Karaoui, L. R. (2021). Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination. American Journal of Health-System Pharmacy, 78(8), 674-683.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttps://academic.oup.com/ajhp/article/78/8/674/6134520?login=trueenAmerican Journal of Health-System Pharmacyinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/134612022-04-06T12:43:27Z |
| spellingShingle | Imipenem/cilastatin/relebactam Mansour, Hanine |
| status_str | publishedVersion |
| title | Imipenem/cilastatin/relebactam |
| title_full | Imipenem/cilastatin/relebactam |
| title_fullStr | Imipenem/cilastatin/relebactam |
| title_full_unstemmed | Imipenem/cilastatin/relebactam |
| title_short | Imipenem/cilastatin/relebactam |
| title_sort | Imipenem/cilastatin/relebactam |
| url | http://hdl.handle.net/10725/13461 https://doi.org/10.1093/ajhp/zxab012 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://academic.oup.com/ajhp/article/78/8/674/6134520?login=true |